Letermovir
Back to searchMolecule Structure
Scientific Name
Letermovir
Description of the Drug
Letermovir is an antiviral medication used to treat CMV infections and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT).
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB12070
http://www.drugbank.ca/drugs/DB12070
Brand Name(s)
Prevymis
Company Owner(s)
Merck Sharp And Dohme Corp
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| DNA terminase | PROTEIN COMPLEX | INHIBITOR | CHEMBL3991482 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL379403 | |
| DrugBank | DB12070 | |
| PubChem: Thomson Pharma | 92388531 | |
| PubChem | 45138674 | |
| LINCS | LSM-45820 | |
| Nikkaji | J3.556.145E | |
| EPA CompTox Dashboard | DTXSID40238683 | |
| DrugCentral | 5262 | |
| ChemicalBook | CB92627305 | |
| rxnorm | PREVYMIS | LETERMOVIR |
| PubChem: Drugs of the Future | 123055444 | |
| ZINC | ZINC000100369359 |
